Search

Your search keyword '"Cantiello F"' showing total 232 results
Start Over Author "Cantiello F"
232 results on '"Cantiello F"'

1. Impact of treatment of BPH-related LUTS with second generation temporary implantable nitinol device (iTIND) on serum PSA: Results from a multicenter prospective study (MT-06-study)

Author

De Cillis, S.T., primary, Amparore, D., additional, Checcucci, E., additional, Piramide, F., additional, Piana, A., additional, Volpi, G., additional, Sica, M., additional, Meziere, J., additional, Schönthaler, M., additional, Robert, G., additional, Di Dio, M., additional, Cantiello, F., additional, Gómez Sancha, F., additional, Becker, A., additional, Terrone, C., additional, Beverini, M., additional, Parodi, S., additional, De Nunzio, C., additional, Muellhaupt, G., additional, Delongchamps, N.B., additional, Della Negra, E., additional, Woo, H., additional, Fiori, C., additional, and Porpiglia, F., additional

Published
2024
Full Text
View/download PDF

2. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

Author

Ferro, M., Di Lorenzo, G., Vartolomei, M. D., Bruzzese, D., Cantiello, F., Lucarelli, G., Musi, G., Di Stasi, S., Hurle, R., Guazzoni, G., Busetto, G. M., Gabriele, A., Del Giudice, F., Damiano, R., Perri, F., Perdona, S., Verze, P., Borghesi, M., Schiavina, R., Almeida, G. L., Bove, P., Lima, E., Autorino, R., Crisan, N., Farhan, A. R. Abu, Battaglia, M., Russo, G. I., Ieluzzi, Vincenzo, Morgia, G., De Placido, P., Terracciano, D., Cimmino, A., Scafuri, L., Mirone, V., De Cobelli, O., Shariat, S., Sonpavde, Guru, and Buonerba, C.

Published
2020
Full Text
View/download PDF

3. Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database

Author

Marchioni, M., primary, Porreca, A., additional, Di Nicola, M., additional, Lucarelli, G., additional, Dorin, V.M., additional, Soria, F., additional, Terracciano, D., additional, Mistretta, F.A., additional, Buonerba, C., additional, Cantiello, F., additional, Mari, A., additional, Minervini, A., additional, Veccia, A., additional, Musi, G., additional, Hurle, R., additional, Busetto, G.M., additional, Del Giudice, F., additional, Chung, B.I., additional, Berardinelli, F., additional, Perdonà, S., additional, Del Prete, P., additional, Mirone, V., additional, Borghesi, M., additional, Bove, P., additional, Autorino, R., additional, Crisan, N., additional, Battaglia, M., additional, Ditonno, P., additional, Russo, G.I., additional, Muto, M., additional, Damiano, R., additional, Porpiglia, F., additional, de Cobelli, O., additional, Schips, L., additional, and Ferro, M., additional

Published
2022
Full Text
View/download PDF

4. Preoperative predictors of postoperative complications after robot-assisted and laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma

Author

Crocerossa, F., primary, Carbonara, U., additional, Veccia, A., additional, Rosiello, G., additional, Tellini, R., additional, Mari, A., additional, Mastroianni, R., additional, Ferro, M., additional, De Cobelli, O., additional, Cacciamani, G., additional, Minervini, A., additional, Simone, G., additional, Cantiello, F., additional, Damiano, R., additional, and Autorino, R., additional

Published
2022
Full Text
View/download PDF

5. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RANEO) research consortium)

Author

Tafuri, A., primary, Marchioni, M., additional, Cerrato, C., additional, Mari, A., additional, Tellini, R., additional, Odorizzi, K., additional, Veccia, A., additional, Amparore, D., additional, Shakir, A., additional, Carbonara, U., additional, Trovato, F., additional, Catellani, M., additional, Janello, L.M.I., additional, Bianchi, L., additional, Novara, G., additional, Dal Moro, F., additional, Schiavina, R., additional, De Lorenzis, E., additional, Parma, P., additional, Cimino, S., additional, de Cobelli, O., additional, Maiorino, F., additional, Bove, P., additional, Crocerossa, F., additional, Cantiello, F., additional, D’andrea, D., additional, Di Cosmo, F., additional, Porpiglia, F., additional, Ditonno, P., additional, Montanari, E., additional, Soria, F., additional, Gontero, P., additional, Liguori, G., additional, Trombetta, C., additional, Mantica, G., additional, Borghesi, M., additional, Terrone, C., additional, Del Giudice, F., additional, Sciarra, A., additional, Galosi, A., additional, Moschini, M., additional, Shariat, S.F., additional, Di Nicola, M., additional, Minervini, A., additional, Ferro, M., additional, Cerruto, M.A., additional, Schips, L., additional, Pagliarulo, V., additional, and Antonelli, A., additional

Published
2022
Full Text
View/download PDF

9. Renal function variation after nephroureterectomy for upper urinary tract carcinoma: Evaluation in a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium)

Author

Tafuri, A., primary, Marchioni, M., additional, Cerrato, C., additional, Mari, A., additional, Veccia, A., additional, Parma, P., additional, Dal Moro, F., additional, Schiavina, R., additional, Bove, P., additional, Cantiello, F., additional, Porpiglia, F., additional, Ditonno, P., additional, Montanari, E., additional, Gontero, P., additional, Trombetta, C., additional, Terrone, C., additional, Schips, L., additional, Sciarra, A., additional, Galosi, A., additional, Ferro, M., additional, Shariat, S.F., additional, Di Nicola, M., additional, Minervini, A., additional, Pagliarulo, V., additional, and Antonelli, A., additional

Published
2022
Full Text
View/download PDF

12. Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma

Author

Lucarelli, G, Ferro, M, Loizzo, D, Bianchi, C, Terracciano, D, Cantiello, F, Bell, L, Battaglia, S, Porta, C, Gernone, A, Perego, R, Maiorano, E, Cobelli, O, Castellano, G, Vincenti, L, Ditonno, P, Battaglia, M, Lucarelli, Giuseppe, Ferro, Matteo, Loizzo, Davide, Bianchi, Cristina, Terracciano, Daniela, Cantiello, Francesco, Bell, Lauren N., Battaglia, Stefano, Porta, Camillo, Gernone, Angela, Perego, Roberto., Maiorano, Eugenio, Cobelli, Ottavio de, Castellano, Giuseppe, Vincenti, Leonardo, Ditonno, Pasquale, Battaglia, Michele, Lucarelli, G, Ferro, M, Loizzo, D, Bianchi, C, Terracciano, D, Cantiello, F, Bell, L, Battaglia, S, Porta, C, Gernone, A, Perego, R, Maiorano, E, Cobelli, O, Castellano, G, Vincenti, L, Ditonno, P, Battaglia, M, Lucarelli, Giuseppe, Ferro, Matteo, Loizzo, Davide, Bianchi, Cristina, Terracciano, Daniela, Cantiello, Francesco, Bell, Lauren N., Battaglia, Stefano, Porta, Camillo, Gernone, Angela, Perego, Roberto., Maiorano, Eugenio, Cobelli, Ottavio de, Castellano, Giuseppe, Vincenti, Leonardo, Ditonno, Pasquale, and Battaglia, Michele

Abstract

Clear cell renal cell carcinoma (ccRCC) is fundamentally a metabolic disease. Given the importance of lipids in many cellular processes, in this study we delineated a lipidomic profile of human ccRCC and integrated it with transcriptomic data to connect the variations in cancer lipid metabolism with gene expression changes. Untargeted lipidomic analysis was performed on 20 ccRCC and 20 paired normal tissues, using LC-MS and GC-MS. Different lipid classes were altered in cancer compared to normal tissue. Among the long chain fatty acids (LCFAs), significant accumulations of polyunsaturated fatty acids (PUFAs) were found. Integrated lipidomic and transcriptomic analysis showed that fatty acid desaturation and elongation pathways were enriched in neoplastic tissue. Consistent with these findings, we observed increased expression of stearoyl-CoA desaturase(SCD1) and FA elongase 2 and 5 in ccRCC. Primary renal cancer cells treated with a small molecule SCD1 inhibitor (A939572) proliferated at a slower rate than untreated cancer cells. In addition, after cisplatin treatment, the death rate of tumor cells treated with A939572 was significantly greater than that of untreated cancer cells. In conclusion, our findings delineate a ccRCC lipidomic signature and showed that SCD1 inhibition significantly reduced cancer cell proliferation and increased cisplatin sensitivity, suggesting that this pathway can be involved in ccRCC chemotherapy resistance.

Published
2020

15. Trifecta outcomes after percutaneous renal mass ablation: a multicenters analysis

Author

Crocerossa, F., primary, Carbonara, U., additional, Larcher, A., additional, Basile, G., additional, Damiano, R., additional, Cantiello, F., additional, Falagario, U.G., additional, Veccia, A., additional, Ditonno, P., additional, Battaglia, M., additional, Mirono, V., additional, Derweesh, I., additional, Montorsi, F., additional, Capitanio, U., additional, and Autorino, R., additional

Published
2020
Full Text
View/download PDF

17. SC223 - Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RANEO) research consortium)

Author

Tafuri, A., Marchioni, M., Cerrato, C., Mari, A., Tellini, R., Odorizzi, K., Veccia, A., Amparore, D., Shakir, A., Carbonara, U., Trovato, F., Catellani, M., Janello, L.M.I., Bianchi, L., Novara, G., Dal Moro, F., Schiavina, R., De Lorenzis, E., Parma, P., Cimino, S., de Cobelli, O., Maiorino, F., Bove, P., Crocerossa, F., Cantiello, F., D’andrea, D., Di Cosmo, F., Porpiglia, F., Ditonno, P., Montanari, E., Soria, F., Gontero, P., Liguori, G., Trombetta, C., Mantica, G., Borghesi, M., Terrone, C., Del Giudice, F., Sciarra, A., Galosi, A., Moschini, M., Shariat, S.F., Di Nicola, M., Minervini, A., Ferro, M., Cerruto, M.A., Schips, L., Pagliarulo, V., and Antonelli, A.

Published
2022
Full Text
View/download PDF

18. SC221 - Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database

Author

Marchioni, M., Porreca, A., Di Nicola, M., Lucarelli, G., Dorin, V.M., Soria, F., Terracciano, D., Mistretta, F.A., Buonerba, C., Cantiello, F., Mari, A., Minervini, A., Veccia, A., Musi, G., Hurle, R., Busetto, G.M., Del Giudice, F., Chung, B.I., Berardinelli, F., Perdonà, S., Del Prete, P., Mirone, V., Borghesi, M., Bove, P., Autorino, R., Crisan, N., Battaglia, M., Ditonno, P., Russo, G.I., Muto, M., Damiano, R., Porpiglia, F., de Cobelli, O., Schips, L., and Ferro, M.

Published
2022
Full Text
View/download PDF

21. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

Author

Ferro, M., primary, Di Lorenzo, G., additional, Vartolomei, M. D., additional, Bruzzese, D., additional, Cantiello, F., additional, Lucarelli, G., additional, Musi, G., additional, Di Stasi, S., additional, Hurle, R., additional, Guazzoni, G., additional, Busetto, G. M., additional, Gabriele, A., additional, Del Giudice, F., additional, Damiano, R., additional, Perri, F., additional, Perdona, S., additional, Verze, P., additional, Borghesi, M., additional, Schiavina, R., additional, Almeida, G. L., additional, Bove, P., additional, Lima, E., additional, Autorino, R., additional, Crisan, N., additional, Farhan, A. R. Abu, additional, Battaglia, M., additional, Russo, G. I., additional, Ieluzzi, Vincenzo, additional, Morgia, G., additional, De Placido, P., additional, Terracciano, D., additional, Cimmino, A., additional, Scafuri, L., additional, Mirone, V., additional, De Cobelli, O., additional, Shariat, S., additional, Sonpavde, Guru, additional, and Buonerba, C., additional

Published
2019
Full Text
View/download PDF

24. Prognostic role of neutrophil-to-lymphocyte ratio in patients with T1G3 non-muscle invasive bladder cancer

Author

Vartolomei, M.D., primary, Ferro, M., additional, Cantiello, F., additional, Lucarelli, G., additional, Di Stasi, S., additional, Guazzoni, G., additional, Busetto, G.M., additional, De Berardinis, F., additional, Rocco, D., additional, Perdona, S., additional, Verze, P., additional, Borghesi, M., additional, Schiavina, R., additional, Almeida, G., additional, Bove, P., additional, Lima, F., additional, Grimaldi, G., additional, Crisan, N., additional, Abu Farhan, A.R., additional, Battaglia, M., additional, Serretta, V., additional, Russo, G.I., additional, Morgia, G., additional, Mirone, V., additional, De Cobelli, O., additional, and Shariat, S.F., additional

Published
2018
Full Text
View/download PDF

31. Questionnaire based evaluation of prostate biopsy complication comparing different bioptic schemes

Author

Damiano, R., Oliva, A., Cantiello, F., Esposito, C., Perdonà, S., Marco De Sio, Bitonti, M., Sacco, R., D Armiento, M., Damiano, R, Oliva, Adriana, Cantiello, F, Esposito, C, Perdon, S, DE SIO, Marco, Bitonti, M, Sacco, R, D'Armiento, M., Damiano, R., Oliva, A., Cantiello, F., Esposito, Ciro, Perdona, S., De Sio, M., Bitonti, M., and Sacco, R.

Abstract

OBJECTIVES: The systematic parasagittal sextant biopsy technique under transrectal ultrasound guidance, routinely performed to diagnose and stage prostate cancer, has been shown to outperform directed or random biopsies, revolutioning our ability to detect carcinoma of the prostate. Different biopsy schemes have been proposed with similar positive percentage of cancer detection. The present study evaluate from the patient's perspective the complications with the use of two different systematic biopsy protocols with 14 and 8 cores. MATERIAL AND METHODS: Between January 1999 and February 2000, 177 consecutive patients, mean age 64.1 +/- 7.7 years, referred for normal screening digital rectal examination (DRE) and prostate specific antigen (PSA) level 4-10 ng/ml, were submitted to a transrectal US examination followed by lesion directed and 14 scheme systematic biopsies to detect prostate cancer. Biopsies were obtained from conventional sextant biopsies (6 core) and 3 alternate sites which included: the right and left extreme lateral peripheral zone between anterior tissue and posterior gland base (2 core); the right and left transition zone, immediately adjacent to the urethra anterior and posterior (4 core) and the right and left central gland in the mid zone typical of benign prostatic hyperplasia (BPH) (2 core). All specimens were separated for specific location identification. Cancer was identified in 61 patients (34.46%). Traditional sextant biopsies showed 23 patients (37.7%) with positive core to detect cancer, while a sextant regimen incorporating lateral peripheral zone biopsies and transitional zone detected 19 cancer (31.1%). The combination of lateral peripheral and transitional zone alone detected cancer in 59 patients. No cancer was detected in central gland. The lateral peripheral zone was the most frequently positive site biopsy followed by the transitional zone. According the results of our study from April 2000 we started to consider a novel scheme to reduce number of biopsies maintaining the same sensitivity. A subsequent group of 121 patients, mean age 61 +/- 4.6 years, enrolled from April 2000 to May 2001, underwent a transrectal US examination followed by lesion directed and 8 scheme systematic biopsies. None of the patients had previously undergone prostate biopsy. In all patients a visual analog score (VAS) questionnaire about pain and complications was obtained 7 days after the procedure. RESULTS: Of the 149 patients who completed the questionnaire 9.9% found the procedure moderately to extremely painful afterwards, with a VAS > 5, the commonest of these complications being pain and voiding difficulties with a mean value of 15.8%, systemic symptoms as fever or sweats with a mean value of 7.65% of cases. Between the two groups submitted to 14 or 8 scheme biopsies, we detect a statistically significant difference for urethral bleeding (7.3% vs 4.9% p value 0.05) and rectal bleeding (10.3% vs 3.7% p value 0.04), systemic symptoms 10.3% vs 5.0% p value 0.05) and painful voiding afterwards (5.8% vs 2.4% p value 0.02). CONCLUSIONS: Ultrasound guided transrectal biopsy of the prostate is a well tolerated and effective method for obtaining multiple biopsy specimens from the prostate with low incidence of serious complications. The absolute value of referred complications with VAS < 5 results high, but the rate of major complications results low. The 8 biopsy scheme, including sampling in peripherial zone at midgland and transition zone periuretrally toward the base, should be considered in a initial biopsy scheme to reduce number of biopsy and enhancing sensitivity, with a significant less degree of complication rate compared to a extensive 14 biopsy scheme.

Published
2003

32. Reporting Quality of Abstracts Presented at the European Association of Urology Meeting: A Critical Assessment

Author

De Sio M, Yakoubi R, De Nunzio C, Damiano R, Balsamo R, Di Palma C, Cantiello F, Azzarito G, Tubaro A, Autorino R., MIRONE, VINCENZO, DE SIO, Marco, Yakoubi, R, De Nunzio, C, Damiano, R, Balsamo, R, Di Palma, C, Cantiello, F, Azzarito, G, Mirone, V, Tubaro, A, Autorino, Riccardo, De Sio, M, Mirone, Vincenzo, and Autorino, R.

Abstract

PURPOSE: We assessed the reporting quality of randomized and nonrandomized, controlled trials presented in abstract form at the European Association of Urology annual meeting in a 10-year period and determined the impact on subsequent publication. MATERIALS AND METHODS: Abstracts presented at the European Association of Urology annual meetings in 1998, 1999, 2008 and 2009 were retrieved and included in analysis. Two 2-year meeting periods were considered, including 1) 1998 and 1999, and 2) 2008 and 2009. Two standardized forms were constructed based on the CONSORT (Consolidated Standards of Reporting Trials) and STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guidelines, each including 15 and 16 items for randomized and nonrandomized, controlled trials, respectively. Reporting quality was assessed by measuring the proportion of items respected by authors when preparing the abstract, defined as the score ratio. Subsequent full-length publication within 2 years after the meeting was also determined by a PubMed® search. Differences between the 2 periods were analyzed by the chi-square and simple t tests. Predictors of subsequent full-length publication were evaluated by multiple logistic regression using meeting period, topic, country of origin, design, multi-institutional study and the proportion of reported items (score ratio). RESULTS: A total of 3,139 abstracts were included in analysis, of which 375 (11.9%) were randomized, controlled trials. Overall oncology represented the main topic (49.2% of all abstracts). The score ratio (proportion of adequately reported items in each abstract) was better for period 1 than 2 for randomized, controlled trials (63% vs 57%) but better for period 2 than 1 for nonrandomized, controlled trials (55.4% vs 53.2%, each p

Published
2012

35. 514 Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for non-metastatic bladder cancer: Results from a single high-volume institution

Author

Moschini, M., primary, Gandaglia, G., additional, Cucchiara, V., additional, Burgio, G., additional, Mattei, A., additional, Shariat, S., additional, Cantiello, F., additional, Damiano, R., additional, Salonia, A., additional, Briganti, A., additional, Montorsi, F., additional, Colombo, R., additional, and Gallina, A., additional

Published
2016
Full Text
View/download PDF

37. 937 Prognostic value of tumour volume on disease progression of patients treated with radical prostatectomy for node positive prostate cancer

Author

Nini, A., primary, Gandaglia, G., additional, Capitanio, U., additional, Scattoni, V., additional, Zaffuto, E., additional, Bianchi, M., additional, Fossati, N., additional, Mirone, V., additional, Damiano, R., additional, Cantiello, F., additional, Freschi, M., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2015
Full Text
View/download PDF

42. 265 Assessing the optimal extent of salvage lymph node dissection in patients with single pelvic nodal uptake at [11c]-choline pet/ct scan from recurring prostate cancer

Author

Passoni, N.M., primary, Gandaglia, G., additional, Gallina, A., additional, Di Trapani, E., additional, Moschini, M., additional, Nini, A., additional, Larcher, A., additional, Di Muzio, N., additional, Cozzarini, C., additional, Picchio, M., additional, Cucchiara, V., additional, Damiano, R., additional, Cantiello, F., additional, and Briganti, A., additional

Published
2014
Full Text
View/download PDF

43. 714 Tadalafil OaD improves symptoms associated with Peyronie's disease throughout the acute inflammatory phase: Results of a proof of concept psychometric study

Author

Boeri, L., primary, Rocchini, L., additional, Capogrosso, P., additional, Colicchia, M., additional, Serino, A., additional, Ventimiglia, E., additional, Castagna, G., additional, Regina, C., additional, Castiglione, F., additional, Villa, L., additional, Russo, A., additional, Brown, M., additional, Cantiello, F., additional, Damiano, R., additional, and Salonia, A., additional

Published
2014
Full Text
View/download PDF

44. 271 Lymph nodes in prostate cancer patients treated with radical prostatectomy: Oncological outcomes of patients with positive nodes and complications of an extended pelvic lymphadenectomy with robotic assisted approach: Results from a single tertiary care center

Author

Bianchi, M., primary, Abdollah, F., additional, Gallina, A., additional, Suardi, N., additional, Tutolo, M., additional, Moschini, M., additional, Mirone, V., additional, Nini, A., additional, Damiano, R., additional, Zaffuto, E., additional, Cantiello, F., additional, Shariat, S., additional, Guazzoni, G., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2014
Full Text
View/download PDF

46. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.

Author

Di Lorenzo G, Perdonà S, Damiano R, Faiella A, Cantiello F, Pignata S, Ascierto P, Simeone E, De Sio M, Autorino R, Di Lorenzo, Giuseppe, Perdonà, Sisto, Damiano, Rocco, Faiella, Adriana, Cantiello, Francesco, Pignata, Sandro, Ascierto, Paolo, Simeone, Ester, De Sio, Marco, and Autorino, Riccardo

Abstract

Background: The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Guérin (BCG) after BCG failure in high-risk, non-muscle-invasive bladder cancer (BC).Methods: In this multicenter, prospective, randomized, phase 2 trial, eligible patients were those with high-risk non-muscle-invasive BC, failing 1 course of BCG therapy. All patients were randomly allocated to Group A, receiving intravesical gemcitabine (at a dose of 2000 mg/50 mL) twice weekly for 6 consecutive weeks and then weekly for 3 consecutive weeks at 3, 6, and 12 months, or Group B, receiving intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6-week induction course and each week for 3 weeks at 3, 6, and 12 months. Outcome measures were recurrence rate, time to first recurrence, and progression rate. Treatment-related complications were also evaluated.Results: Eighty participants were enrolled, 40 for each group 52.5% in Group A developed disease recurrence versus 87.5% of those in Group B (P = .002). There was no statistically significant difference in mean time to the first recurrence (Group A, 3.9 months; Group B, 3.1 months; P = .09). Kaplan-Meier analysis of 2-year recurrence-free survival showed significant differences between Group A and B (19% and 3%, respectively, P < .008). Seven of 21 (33%) patients in Group A and 13 of 35 (37.5%) patients in Group B had disease progression and underwent radical cystectomy (P = .12). Both intravesical administrations were generally well tolerated.Conclusions: Gemcitabine might represent a second-line treatment option after BCG failure in high-risk non-muscle-invasive BC patients. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results